Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Only Alli Remains After Glaxo’s OTC Transaction With Aspen

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.

Advertisement

Related Content

Perrigo Expands Consumer Business Down Under, Rx Growth Looks Up
Perrigo Expands Consumer Business Down Under, Rx Growth Looks Up
Business & Finance In Brief: GSK | MJN | Actavis | ScripsAmerica
Business & Finance In Brief: GSK | MJN | Actavis | ScripsAmerica
GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives
Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives
Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
GSK Takes Pay-As-You Go Approach In Aspen Branded Generics Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel